K.I. Pritchard

2.7k total citations
35 papers, 1.1k citations indexed

About

K.I. Pritchard is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K.I. Pritchard has authored 35 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K.I. Pritchard's work include Breast Cancer Treatment Studies (20 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (10 papers). K.I. Pritchard is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Cancer Treatment and Pharmacology (11 papers) and HER2/EGFR in Cancer Research (10 papers). K.I. Pritchard collaborates with scholars based in Canada, United States and United Kingdom. K.I. Pritchard's co-authors include Clifford A. Hudis, Robert W. Carlson, Timothy J. Whelan, Mark Levine, Tom Oliver, Robert E. Myers, Mary Johnston, Karen A. Gelmon, Wendy R. Parulekar and Maureen Trudeau and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

K.I. Pritchard

34 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K.I. Pritchard Canada	15	682	580	214	184	183	35	1.1k
Lars Stenbygaard Denmark	12	657 1.0×	516 0.9×	135 0.6×	305 1.7×	137 0.7×	29	1.1k
Holm Eggemann Germany	22	694 1.0×	651 1.1×	214 1.0×	238 1.3×	382 2.1×	76	1.6k
Robert P. Gray United States	15	718 1.1×	859 1.5×	352 1.6×	181 1.0×	174 1.0×	26	1.3k
Nóra Udvarhelyi Hungary	15	324 0.5×	572 1.0×	387 1.8×	125 0.7×	130 0.7×	48	1.2k
Muneaki Sano Japan	19	568 0.8×	400 0.7×	202 0.9×	202 1.1×	115 0.6×	71	1.1k
Knud Andersen Denmark	18	772 1.1×	1.0k 1.7×	500 2.3×	156 0.8×	241 1.3×	31	1.4k
Annabel Goodwin Australia	18	722 1.1×	396 0.7×	149 0.7×	330 1.8×	281 1.5×	45	1.1k
Svjetlana Mohrmann Germany	16	588 0.9×	441 0.8×	160 0.7×	236 1.3×	60 0.3×	63	1.1k
Isabelle Peyrottes France	18	263 0.4×	278 0.5×	155 0.7×	263 1.4×	83 0.5×	41	901
Barbara Fowble United States	12	550 0.8×	631 1.1×	323 1.5×	385 2.1×	146 0.8×	19	1.4k

Countries citing papers authored by K.I. Pritchard

Since Specialization

Citations

This map shows the geographic impact of K.I. Pritchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.I. Pritchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.I. Pritchard more than expected).

Fields of papers citing papers by K.I. Pritchard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.I. Pritchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.I. Pritchard. The network helps show where K.I. Pritchard may publish in the future.

Co-authorship network of co-authors of K.I. Pritchard

This figure shows the co-authorship network connecting the top 25 collaborators of K.I. Pritchard. A scholar is included among the top collaborators of K.I. Pritchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.I. Pritchard. K.I. Pritchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lima, Isac, Meltem Tuna, Chiara Melloni, et al.. (2020). Abstract P5-14-11: Cardiac monitoring in advanced breast cancer patients treated with trastuzumab: Does it improve cardiac safety?. Cancer Research. 80(4_Supplement). P5–14. 1 indexed citations

Jerzak, Katarzyna J., Gerald Lebovic, Paula A. Rochon, et al.. (2019). Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study. Supportive Care in Cancer. 27(8). 3035–3043. 21 indexed citations

Lambertini, Matteo, Christine Campbell, José Bines, et al.. (2017). Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06). Annals of Oncology. 28. v47–v47. 1 indexed citations

Goodwin, Pamela J., Wendy R. Parulekar, Karen A. Gelmon, et al.. (2015). Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. JNCI Journal of the National Cancer Institute. 107(3). djv006–djv006. 93 indexed citations

Buckstein, Rena, Graeme Fraser, Matthew C. Cheung, et al.. (2015). Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. Clinical Lymphoma Myeloma & Leukemia. 16(1). 18–28.e4. 11 indexed citations

Perez, EA, Eileen Holmes, Evandro de Azambuja, et al.. (2014). Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc). Annals of Oncology. 25. v1–v1. 2 indexed citations

Hilton, John, Bin Dong, Judith‐Anne W. Chapman, et al.. (2013). Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Research and Treatment. 142(1). 143–151. 12 indexed citations

Shepherd, L. E., Karen A. Gelmon, Barbara Walley, et al.. (2012). Abstract P1-13-01: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis.. Cancer Research. 72(24_Supplement). P1–13. 3 indexed citations

Kelly, Catherine M. & K.I. Pritchard. (2012). Response. JNCI Journal of the National Cancer Institute. 104(16). 1268–1268. 1 indexed citations

10.

Whelan, Timothy J., Ivo A. Olivotto, Ida Ackerman, et al.. (2011). NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.. Journal of Clinical Oncology. 29(18_suppl). LBA1003–LBA1003. 177 indexed citations

11.

Smith, Ian E., Jean‐Yves Pierga, Laura Biganzoli, et al.. (2010). First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology. 22(3). 595–602. 81 indexed citations

12.

Carlson, Robert W., Clifford A. Hudis, & K.I. Pritchard. (2006). Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations. Journal of the National Comprehensive Cancer Network. 4(10). 971–979. 103 indexed citations

13.

Trudeau, Maureen, Karen A. Gelmon, Kara Laing, et al.. (2005). Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. The Lancet Oncology. 6(11). 886–898. 106 indexed citations

14.

Pritchard, K.I. & Timothy J. Whelan. (2005). Clinical trial update: National Cancer Institute of Canada. Breast Cancer Research. 7(2). 48–51. 8 indexed citations

15.

Myers, Robert E., Mary Johnston, K.I. Pritchard, Mark Levine, & Tom Oliver. (2001). Baseline staging tests in primary breast cancer: a practice guideline.. PubMed. 164(10). 1439–44. 91 indexed citations

16.

Roy, J.A., C. Sawka, & K.I. Pritchard. (1996). Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?. Journal of Clinical Oncology. 14(3). 997–1006. 42 indexed citations

17.

Chapman, Judy‐Anne W., B.G. Mobbs, David R. McCready, et al.. (1996). An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. The Journal of Steroid Biochemistry and Molecular Biology. 57(5-6). 323–328. 16 indexed citations

18.

Chapman, Judy‐Anne W., David Murray, David R. McCready, et al.. (1996). An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer?. European Journal of Cancer. 32(11). 1949–1956. 9 indexed citations

19.

Mobbs, B.G., et al.. (1987). Estrogen and progesterone receptor content of primary and secondary breast carcinoma: Influence of time and treatment. European Journal of Cancer and Clinical Oncology. 23(6). 819–826. 44 indexed citations

20.

Band, Pierre R., J. Maroun, K.I. Pritchard, et al.. (1986). Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.. PubMed. 70(11). 1305–10. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact